Eye Drops, Laser, or Surgery? Understanding Your Glaucoma Treatment Options in Ghana

If you or a family member has been diagnosed with glaucoma, one of the first — and most pressing — questions is: what happens now? What will treatment look like? Will it be drops every day for the rest of your life? Does laser mean surgery? Will surgery take your remaining vision or protect it?

These are the questions patients bring to St. Thomas Eye Hospital regularly. The honest answers require context, because glaucoma treatment in Ghana operates differently from what international articles describe.

There are different cost structures, different insurance realities, different drug availability, and a patient population that typically presents with more advanced disease than in high-income countries.

This guide walks through every tier of glaucoma treatment, what each option does, how the decision is made to escalate, and what is specifically available in Ghana.

One Thing to Understand Before We Begin

Glaucoma treatment has one goal: to lower the intraocular pressure (IOP) inside the eye to protect the optic nerve from further damage. 

All three treatment categories — drops, laser, and surgery — achieve this through different mechanisms. None of them can restore vision that has already been lost. This is why the treatment decisions you make today matter so much: they are about protecting what remains.

Treatment is also lifelong. There is no point at which glaucoma is “cured” and treatment can stop. The pressure must be managed continuously, and the optic nerve monitored regularly, for the rest of the patient’s life.

Tier 1 · First-Line Treatment

Medicated Eye Drops

For most newly diagnosed glaucoma patients in Ghana, the first treatment prescribed is a topical (eye drop) medication.

These drops work by either reducing the amount of fluid the eye produces, improving the drainage of that fluid, or both — bringing intraocular pressure down to a level where the optic nerve is protected from further damage.

Eye drops do not feel different from day to day. They do not improve your vision. They do not make your eye feel better. Their job is to keep the pressure low and invisible — protecting the nerve you cannot see, from damage you cannot feel.

This is why so many patients stop them: there is no tangible sensation of benefit. But the consequence of stopping, as we explored in our previous glaucoma article, is that the pressure rises silently and the nerve continues to be damaged.

The Main Drug Classes Used in Ghana

Drug Class	How It Works	Dosing	NHIA/Cost
Prostaglandin Analogues Latanoprost, Travoprost, Bimatoprost	Increases fluid outflow through the uveoscleral pathway — like opening the drain	Once daily (evening)	Out-of-pocket First-line (Ghana STG)
Beta-Blockers Timolol	Reduces fluid production in the eye — like turning down the tap	Once or twice daily	NHIA covered
Carbonic Anhydrase Inhibitors Dorzolamide, Brinzolamide	Inhibits fluid production via enzyme pathway; used as add-on therapy	Twice daily	Out-of-pocket
Alpha Agonists Brimonidine	Reduces production and increases drainage of fluid	Twice daily	Out-of-pocket
Combination Drops e.g. Dorzolamide/Timolol	Two mechanisms in one bottle — simplifies adherence for multi-drug regimens	Twice daily	Out-of-pocket

The NHIA and Glaucoma Drops — What Patients Need to Know

A critical finding from research at Korle-Bu Teaching Hospital: prostaglandin analogues — Ghana’s recommended first-line glaucoma medication — are not covered by NHIA. They must be paid out of pocket.

This creates a real affordability problem, particularly since prostaglandins are significantly more expensive than beta-blockers. The median monthly cost of glaucoma therapy at Korle-Bu was approximately GHC 65 (around US$16) — a persistent burden for patients who need these medications indefinitely.

If cost is a barrier, speak to your specialist. Timolol (a beta-blocker covered by NHIA) is a legitimate and effective alternative for many patients, particularly those without contraindications such as asthma or heart conditions.

Generic versions of prostaglandins are also available at lower cost than branded equivalents. Do not stop treatment because of cost without discussing alternatives with your doctor first.

When a single drop does not achieve the target pressure, a second drop of a different class is added, or a combination formulation is prescribed to reduce the number of bottles. Most patients with moderate disease are managed on one to two drops.

Adherence — using the drops every day as prescribed — is the single biggest determinant of whether medication controls glaucoma effectively. Missing doses, even occasionally, allows pressure spikes that can accelerate nerve damage.

Tier 2 · Laser Treatment

Selective Laser Trabeculoplasty (SLT) & Beyond

Laser treatment for glaucoma has undergone a significant shift in how it is positioned globally. For most of its history, laser was considered a step you took when drops were no longer working. 

The evidence now supports laser — specifically Selective Laser Trabeculoplasty (SLT) — as a legitimate first-line treatment option, particularly important in the Ghanaian context.

Selective Laser Trabeculoplasty (SLT)

SLT works by applying short pulses of low-energy laser light to the eye’s natural drainage system (the trabecular meshwork), stimulating a biological response that improves fluid outflow and reduces intraocular pressure — without damaging the surrounding tissue.

Why SLT Matters Particularly for Ghanaian Patients

• Cost over time: Research shows SLT becomes more cost-effective than prostaglandin drops within about one year — a major advantage when NHIA doesn’t cover first-line drops
• Adherence: A one-time outpatient procedure eliminates the daily compliance burden that undermines drop therapy in Ghana
• Safety: No serious complications were recorded in the Ghana SLT audit; the procedure is outpatient and takes minutes
• Repeatability: SLT can be repeated if the initial effect diminishes over time
• Advanced disease context: SLT can be used as adjunctive therapy even when drops are already in use, to reduce medication burden

Micropulse Transscleral Cyclophotocoagulation (TSCPC)

For patients with more advanced glaucoma or where standard laser has not achieved adequate pressure control, a more targeted approach is available: Micropulse TSCPC.

This procedure uses a specially calibrated laser delivered across the sclera (the white of the eye) to reduce the eye’s fluid production by treating the ciliary body — the structure responsible for producing aqueous humour.

Unlike older, continuous-wave cyclophotocoagulation — which carried risks of significant inflammation and vision loss — micropulse technology delivers energy in pulses, allowing tissue to cool between pulses and dramatically reducing the risk of collateral damage. 

St. Thomas Eye Hospital is currently the only facility in Ghana offering Micropulse TSCPC technology, making it the national referral point for patients with refractory glaucoma that has not responded adequately to drops or SLT.

Laser Peripheral Iridotomy (LPI)

For patients with narrow-angle or angle-closure glaucoma — a different, often more acute form of the disease — LPI is the appropriate laser treatment. A small opening is created in the iris using a laser, allowing fluid to flow freely and preventing dangerous pressure spikes.

This is a preventive procedure as much as a treatment, and is often recommended for patients with anatomically narrow drainage angles before they develop an acute attack.

Tier 3 · Surgical Treatment

Trabeculectomy & Drainage Device Implantation

Surgery for glaucoma is not a last resort in the sense of “there is nothing else we can do.”

It is a clinically indicated escalation — recommended when drops and laser have not achieved adequate IOP control, when the optic nerve is deteriorating despite medical management, or when the severity of disease at presentation demands more aggressive intervention from the outset.

In Ghana, where many patients present with advanced glaucoma, surgery is often part of the management picture earlier than in countries where earlier detection is the norm.

Trabeculectomy

Trabeculectomy is the most widely performed surgical procedure for glaucoma globally, and the standard surgical option in Ghana.

The surgeon creates a small flap in the sclera that allows excess fluid to drain from the eye into a small fluid-filled reservoir (bleb) under the upper eyelid, from where it is gradually absorbed. This creates a new, permanent drainage pathway that significantly lowers IOP.

Trabeculectomy achieves approximately 80% success in reducing IOP to target levels when augmented with anti-metabolites (mitomycin-C or 5-fluorouracil), which reduce scarring at the surgical site that would otherwise block the new drainage channel.

In Ghana, trabeculectomy failure rates have historically been higher than in Caucasian populations — a known challenge in African patients — making the use of anti-metabolites and careful post-operative management critical to outcomes.

What to Expect with Trabeculectomy

• Performed in an operating theatre under local anaesthesia; day surgery or short admission
• Frequent post-operative review in the first weeks — the bleb must be monitored and managed carefully
• Activity restrictions for several weeks: no heavy lifting, swimming, eye rubbing
• Most patients still require some drops after surgery — the goal is IOP reduction, not necessarily drop elimination
• Long-term follow-up is essential; bleb failure can occur months to years later
• If one trabeculectomy fails, a repeat procedure or drainage device may be considered

Glaucoma Drainage Devices

For patients whose glaucoma cannot be adequately controlled by trabeculectomy — including those with neovascular glaucoma (often linked to diabetes), failed prior surgery, or other complex secondary glaucomas — drainage device implantation offers an alternative surgical approach.

A small tube is placed in the eye, connected to a plate implanted under the conjunctiva that acts as a reservoir, allowing fluid to drain continuously at controlled levels.

Ghana’s Only Facility for Advanced Drainage Devices

St. Thomas Eye Hospital is currently the only facility in Ghana performing implantation of all three major glaucoma drainage devices:

• Ahmed Glaucoma Valve — the most widely used device globally for refractory glaucoma; contains a flow-regulating valve to prevent hypotony (dangerously low pressure)
• AADI (Aurolab Aqueous Drainage Implant) — a cost-effective alternative to the Ahmed valve, validated in multiple African populations
• Molteno Shunt — one of the earliest and most established drainage devices; appropriate for complex cases requiring sustained long-term drainage

Patients from across Ghana who require these devices are referred to St. Thomas. If you have been told you need a glaucoma drainage device and cannot find a facility near you, contact our team.

Ongoing · The Fourth Treatment

Monitoring — The Part Most Patients Underestimate

Glaucoma management is not just about what treatment you are on — it is about how consistently your condition is being measured.

Monitoring is the mechanism that tells your specialist whether your current treatment is working, whether the optic nerve is stable or deteriorating, and whether treatment needs to be changed. Without it, you are managing blind.

A typical glaucoma monitoring schedule includes:

• IOP measurement — at every visit; the primary indicator of treatment effectiveness
• OCT of the retinal nerve fibre layer — typically every 6–12 months; detects structural deterioration before vision is affected
• Visual field testing (perimetry) — every 6–12 months; maps any functional vision loss in the peripheral field
• Optic disc photography — annual or biannual; documents structural changes in the nerve over time
• Review of drop adherence and technique — incorrect drop instillation is a common cause of inadequate IOP control

A diagnosis without follow-up is a paper exercise. The treatment only protects your vision if the monitoring confirms it is working, and adjustments are made when it is not.

The Treatment Is Here. The Window Is Now.

The most important thing to understand about glaucoma treatment in Ghana in 2026 is this: the full spectrum of care is available. From first-line drops to SLT laser to micropulse technology to Ahmed valve surgery — all of it exists at St. Thomas Eye Hospital.

The treatment pyramid is complete.

What is not complete is the uptake. The majority of Ghanaians with glaucoma are undiagnosed. Of those diagnosed, many are on medication they inconsistently take. Of those who need laser or surgery, fear or misinformation keeps them waiting until there is less vision left to save.

If you have been diagnosed with glaucoma, this article exists to show you that treatment is not a single frightening event — it is a managed, tiered journey, with clinical expertise guiding every decision.

If you have not been diagnosed but carry risk factors, it exists to show you that a one-hour specialist examination could be the most important health decision you make this year.

The pressure in your eye is measurable. The nerve is imageable. The options are available. All that is required is for you to come in.

Book a glaucoma assessment at St Thomas Eye Hospital, Ghana’s most advanced glaucoma diagnostic and treatment centre.

Walk-ins welcome · NHIA accepted · Monday – Saturday, at any of our branches at Osu, Mataheko, Labadi, Tema, Kumasi (Ahodwo), Takoradi.